



BIBLIOGRAPHY

- [1] King, H., Aubert, R., & Herman, W. (1998). Global Burden of Diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care, (21), 1414–1431.
- [2] Section of Non-communicable Diseases, Bureau of Epidemiology, Department of Disease Control, Ministry of Public Health, Thailand. (2002). Rate of Importance Non-communicable Disease. Retrieved on July, 21, 2005 from: <http://epid.moph.go.th/NCDweb2/statistic.pdf>.
- [3] Health systems research institute. (2003). Diabetes registry project 2003. Bangkok: Health systems research institute.
- [4] Yacg, D. et al. (2004). The Global burden of chronic diseases: overcoming impediments to prevention and control. JAMA, 291(21), 2616-2622.
- [5] Wake, N. et al. (2000). Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes research and clinical practice, (48), 201-210.
- [6] O'Brien, J.A., Patrick, A.R., & Caro, J. (2002). Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clinical Therapeutics, 25(3), 1017-1038.
- [7] Yuphakdee, N., & Pannarunothai S. (2005). Feasibility of an outpatient case mix classification system based on the health insurance database in Thailand. Journal of health science, 14(1), 233-241.
- [8] UKPDS group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, (352), 837-853.
- [9] Asian-pacific type 2 diabetes policy group. (2005) Type 2 diabetes practical targets and treatments. Melbourne: the International Diabetes Institute (IDI)

- [10] Turner, R.C. et al. (1999). Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS49). JAMA, 281(21), 2005-2012.
- [11] Hayward, R.A. et al., (1997). Starting insulin therapy in patients with type 2 diabetes, Effectiveness, complications and resource utilization. JAMA, 278, 1663-1669.
- [12] Pawasutipisit, A., & Chansrisutiyawong, A., (2004). The evaluation of errors in insulin drawing-up technique into syringe by diabetic patients. Thai J Hosp Pharm, 14(3), 211-224.
- [13] van Wijk, J.P. et al. (2003). Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol, 23(10), 1744-1749.
- [14] Chiquette, E., Ramirez, G., & DeFronzo, R., (2004). A Meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med, 164, 2094-2104.
- [15] Dormandy, J.A., et al. (2005). Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (prospective pioglitazone clinical trial in macrovascular event): a randomized controlled trial. Lancet, 366(9493), 1279-1289.
- [16] National drug committee, (2004) National list of essential medicines. Bangkok: Ministry of public health.
- [17] Vondeling, H., & Iversen, P.B. (2004). Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies. Eur J Health Econ, 5(3), 263-269.
- [18] Neeser, K., et al. (2004). Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective. Pharmacoeconomics, 22(5), 321-341.
- [19] Henriksson, F. (2002). Applications of economic models in healthcare: the introduction of pioglitazone in Sweden. Pharmacoeconomics, 20(1), 43-53.
- [20] Plosker, G.L., & Figgitt, D.P. (2004). Repaglinide: a pharmacoeconomic review of its use in type 2 diabetes mellitus. Pharmacoeconomics, 22(6), 389-411.

- [21] Czoski-Murray, C., et al. (2004). Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess, 8(13), 1-91.
- [22] Veenstra, D.L., Ramsey, S.D., & Sullivan, S.D. (2002). A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment. Pharmacoeconomics, 20(1), 21-30.
- [23] The expert committee on the diagnosis and classification of diabetes mellitus. (2003). Report of the Expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 26, 5-20.
- [24] American diabetes association. (2005). Standards of medical care in diabetes. Diabetes Care, 28(1), 4-36.
- [25] Diabetes control and complications trial/epidemiology of diabetes interventions and complication (DCCT-EDIC) research group. (2000). Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy, N Engl J Med, 342, 381-389.
- [26] Rohlfing, C.L., et al. (2002). Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the diabetes control and complications trial. Diabetes Care, 48, 436-472.
- [27] Herfindal, E.T., & Gourley, D.R. (2000). Textbook of therapeutics: drug and disease management (7th ed.). Philadelphia: Lippincott Williams&Wilkins.
- [28] Drummond, M.F., et al. (1997). Methods for the economic evaluation of health care programmes. (2nd ed.). Toronto: Oxford university press.
- [29] Fleming, T.R., & DeMets, D.L., (1996) .Surrogate end points in clinical trials: Are we being misled? Ann Intern Med, 125, 605-613.
- [30] Weinstein, M.C., et al. (2003).the ISPOR Task Force on Good Research Practices– Modeling Studies: Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health, 6, 9-17.

- [31] Palmer, A.J., et al., (2004) .The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Cost-effectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making. Curr Med Res Opin, 20(1), 5-26.
- [32] American diabetes association consensus panel. (2004). Guidelines for computer modeling of diabetes and its complications. Diabetes Care, 27(9), 2262-2265.
- [33] Eastman, R.C., et al (1997).Model of complications of NIDDM. I. Model construction and assumptions. Diabetes Care, 20, 725-734.
- [34] Brown, J.B., et al., (2005). The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract, 50(3), 15-46.
- [35] Eddy, D.M., & Schlessinger, L. (2003).Archimedes: a trial-validated model of diabetes. Diabetes Care, 26, 3093-3101.
- [36] Stevens, R., et al. (2001).The UKPDS risk engine: a model for the risk of coronary heart disease in type 2 diabetes (UKPDS 56). Clin Sci, 101, 671-679.
- [37] Bagust, A., et al. (2001). An economic model of the long-term health care burden of Type II diabetes. Diabetologia, 44, 2140-2155.
- [38] Clarke, P.M., et al., (2004). A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia, 47(10), 1747-1759.
- [39] Palmer, A.J., et al. (2004).Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin, 20(1), 27-24.
- [40] D'Agostino, RB. et al. (2000). Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J, 139(2), 272-281.
- [41] Kannel, WB. et al., (1999). Profile for estimating risk of heart failure in Framingham Heart Study subjects. Circulation, 159(11), 1197-1204.
- [42] Wolf, PA. et al. (1991).Probability of stroke: a risk profile from the Framingham study. Stroke, 22, 312-318.
- [43] Kothari, V. et al., (2002). UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke, 33(7), 1776-1781

- [44] Stratton, I.M., et al. (2001). UKPDS50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia, 44(2), 156-163.
- [45] Partanen, J., et al. (1995). Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus, N Engl J Med, 333(2), 89-94
- [46] Tennvall, G.R., & Apelqvist, J., (2001). Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations. Diabetologia, 44, 2077-2087.
- [47] Javitt, J.C. et al., (1994). Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care, 17(8), 909-917.
- [48] Klein, R., Klein, B.E.K., & Moss, S.E. (1989). The Wisconsin Epidemiology study of Diabetic Retinopathy. IX. Four year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol, 107, 237-243.
- [49] Stratton, IM. et al., (2000). Association of hypoglycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321(7258), 405-412.
- [50] Ritz, E., & Stefanski, A. (1996). Diabetic nephropathy in type II diabetes. Am J Kidney Dis, 27(2), 167-194.
- [51] Ravid, M. et al., (1998). Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hypoglycemia. Arch Intern Med, 118(8), 577-581.
- [52] Lewis, E.J. et al. (1993). The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med, 329, 1456-1462.
- [53] Wolfe, R.A. et al., (1999). Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med, 341(23), 1725-1730.

- [54] Campbell, I.W. (1985). Metformin and the sulphonylureas: the comparative risk. Horm Metab Res, 15, 105-111.
- [55] Aekplakorn, W. et al. (2003). The prevalence and management of diabetes in Thai adult. Diabetes care, 26(10), 2758-2763.
- [56] Health promotion foundation, Thailand, (2003). Alcohol consumption in Thailand. Retrieved on Nov 11, 2005 from: <http://www.thaihealth.or.th/content.php?SystemModuleKey=situationalcohol&id=2840>.
- [57] National statistical office Thailand. (2004). Tobacco and alcohol consumption in Thai population 2004. Retrieved on Nov 11, 2005 from: http://service.nso.go.th/nso/data/data23/stat_23/toc_4/4.4-5-47.xls.
- [58]. Sriratanasathavorn, C. et al. (2000). The prevalence of left ventricular hypertrophy and associated factors in a Thai population. J Med Assoc Thai, 83(2), 218-222.
- [59] Nitiapinyasakul, N., & Nitiapinyasakul, A. (2004). Diabetic retinopathy screening in community hospitals. Thai J Ophthalmol, 18(2), 103-110.
- [60] Pongchaiyakul, C., & Tandhanand, S. (2006). Improvement of diabetes care at Maharat Nakhon Ratchasima hospital (The study of diabcare-Asia from 1997 to 2003). J Med Assoc Thai, 89(1), 56-62.
- [61] Kittimanon, N., Sirikulsatean, V., & Pipatsat, R. (2005). Integrated care for type 2 diabetic patients at Aumthur Mueng, Phitsanulok Province. Buddhachinaraj Medical Journal, 22(2), 155-168.
- [62] Niemeyer, N.V., & Janney, L.M., (2002). Thiazolidinedione-induced edema. Pharmacotherapy, 22(7), 924-929.
- [63] Wilson Tang, WH. et al. (2003). Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol, 41(8), 1394-1398.
- [64] Guan, Y.F., Hao, C., Cha, DR., Rao, R. et al. (2005). Thiazolidinediones expand body fluid volume through PPAR-gamma stimulation of ENAC-mediated renal salt absorption. Nature medicine, 11(8), 861-865.

- [65] Hussein, Z. et al. (2004). Effectiveness and side effects of thiazolidinediones for type 2 diabetes: real-life experience from a tertiary hospital. MJA, 181(10), 536-539.
- [66] King, A.B., (2000). A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes care, 23(4), 557.
- [67] Goldberg, R.B. et al. (2005). A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes care, 28(7), 1547-1554.
- [68] Murabito, J.M. et al., (1997). A risk profile from the Framingham Heart Study. Circulation, 96(1), 44-49.
- [69] Stratton, I.M. et al., (2001). UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. Diabetologia, 44(2), 156-163.
- [70] Adler, A.I. et al. (2000). Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study, BMJ, 321(7258), 412-419.
- [71] UKPDS group, (1998). Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 352, 854-865.
- [72] UKPDS group. (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 317, 703-713.
- [73] Krairitichai, U. et al. (2003). Thailand registry of renal replacement therapy. Journal of the Nephrology Society of Thailand, 9(3), 210-225.
- [74] Bureau of Trade and Economic Indices, Ministry of Commerce, Thailand (2005) Consumer price index. Retrieved on May 5, 2005 from:
<http://www.indexpr.moc.go.th/>
- [75] Buddhachinaraj hospital. (2004). Buddhachinaraj hospital annually report.
Phitsanulok: Buddhachinaraj hospital.

- [76] Tisayathikom, K. et al. (2001). Cost and efficiency of public and private hemodialysis centers in 2001. Nonthaburi: International Health Policy Program
- [77] Teerawattananon, Y. (2005). Cost-effectiveness and cost-utility analysis of renal replacement therapy in Thailand. In Tangcharearnsatien, V. et al. (Eds.), Universal access to renal replacement therapy in Thailand: a policy analysis(p.113-137). Bangkok: International Health Policy Program.
- [78] Tangcharearnsatien, V. et al. (2001). The policy analysis of renal replacement therapy for end stage renal disease patients in basic care package of universal health insurance in Thailand. Thai Med Counc Bull, 30, 215-226.
- [79] Pornpinatepong, S. (2005). Cost-effectiveness analysis of diabetic retinopathy screening in Type 2 diabetes mellitus. Master thesis, Mahidol University, Bangkok.
- [80] Drug&Medical Supply Information Center, (DMSCI), (2005). The reference costs of national of public health. Retrieved on Jan 23, 2005 from: <http://dmsic.moph.go.th/price.htm>.
- [81] National health security office, Thailand, (2002). Thai DRGs, version3. Bangkok: Ministry of public health
- [82] National health security office, Thailand, (2005). Guideline for budget management in 2005 fiscal year. Retrived on Jan 2, 2006 from: <http://www.nhso.go.th/>.
- [83] Drummond , MF. et al. (2005). Methods for the economic evaluation of health care programmes. (3 ed). Toronto: Oxford press.
- [84] Tan-Torres Edejer, T., Baltussen, R., & Adam, T., (Eds). (2003). Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization.
- [85] Diabetes control and complications trial/epidemiology of diabetes interventions and complication (DCCT-EDIC) research group. (2005). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med, 353, 2643-2653.

- [86] The World Health Organization (WHO). (2000). Cost-effectiveness thresholds (2000 International \$); by Region. Retrived on June 2006 from:
http://www.who.int/choice/costs/CER_thresholds_regions.xls:
- [87] WHO Commission on Macroeconomic and Health. (2001). Macroeconomics and health: investing in health for economic development: Report of the Commission on Macroeconomics and Health. Geneva: the World Health organization.
- [88] Eichler, HG. et al. (2004). Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value in health, 7(5), 518-528.
- [89] Palmer, A.J. et al. (2000). Outline of a diabetes disease management model: principles and applications. Diabetes Res Clin Pract, 50(3), 47-56.
- [90] Kunaratanapruk, S., et al. (1995). Medical care price schedules for road traffic accidents: The Thai DRG for Accidents. Phitsanulok: Centre for Health Equity Monitoring